The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis
Open accessAbstract
An important goal of the health system is to identify new adverse drug events (ADEs) in the postapproval period. Datamining methods that can transform data into meaningful knowledge to inform patient safety have proven essential for this purpose. New opportunities have emerged to harness data sources that have not been used within the traditional framework. This article provides an overview of recent methodological innovations and data sources used to support ADE discovery and analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mining association rules between sets of items in large databases
Agrawal, R., Imieliński, T., & Swami, A. (1993) · Proceedings of the 1993 ACM SIGMOD international conference on Management of data · doi:10.1145/170035.170072 · Cited by 14,907
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807
Mining association rules between sets of items in large databases
Agrawal, R., Imieliński, T., & Swami, A. (1993) · ACM SIGMOD Record · doi:10.1145/170036.170072 · Cited by 4,551
DrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861
A Bayesian neural network method for adverse drug reaction signal generation
Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lansner, A., & De Freitas, R. M. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050466 · Cited by 1,476
A review of uses of health care utilization databases for epidemiologic research on therapeutics
Schneeweiss, S., & Avorn, J. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.10.012 · Cited by 1,277
Classen, D. C. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540280039031 · Cited by 1,134
Schneeweiss, S., Rassen, J. A., Glynn, R. J., Avorn, J., Mogun, H., & Brookhart, M. A. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a663cc · Cited by 1,128
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Quantitative signal detection using spontaneous ADR reporting
Bate, A., & Evans, S. J. W. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1742 · Cited by 912
Dumouchel, W. (1999) · The American Statistician · doi:10.1080/00031305.1999.10474456 · Cited by 878
Self-citationLarge-Scale Bayesian Logistic Regression for Text Categorization
Genkin, A., Lewis, D. D., & Madigan, D. (2007) · Technometrics · doi:10.1198/004017007000000245 · Cited by 808
Self-citationSzarfman, A., Machado, S. G., & O??Neill, R. T. (2002) · Drug Safety · doi:10.2165/00002018-200225060-00001 · Cited by 700
Molecular similarity: a key technique in molecular informatics
Bender, A., & Glen, R. C. (2004) · Organic & Biomolecular Chemistry · doi:10.1039/b409813g · Cited by 614
Wysowski, D. K., & Swartz, L. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1363 · Cited by 471
Stang, P. E., Ryan, P. B., Racoosin, J. A., Overhage, J. M., Hartzema, A. G., Reich, C., Welebob, E., Scarnecchia, T., & Woodcock, J. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-9-201011020-00010 · Cited by 441
Self-citationConfounding Control in Healthcare Database Research: Challenges and Potential Approaches
Brookhart, M. A., Stürmer, T., Glynn, R. J., Rassen, J., & Schneeweiss, S. (2010) · Medical Care · doi:10.1097/mlr.0b013e3181dbebe3 · Cited by 377
Wicks, P., Vaughan, T. E., Massagli, M. P., & Heywood, J. (2011) · Nature Biotechnology · doi:10.1038/nbt.1837 · Cited by 362
Estimating Treatment Effects Using Observational Data
D’Agostino, R. B. (2007) · JAMA · doi:10.1001/jama.297.3.314 · Cited by 350
Chapman, W. W., Nadkarni, P. M., Hirschman, L., D'Avolio, L. W., Savova, G. K., & Uzuner, O. (2011) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000465 · Cited by 296
The National Center for Biomedical Ontology
Musen, M. A., Noy, N. F., Shah, N. H., Whetzel, P. L., Chute, C. G., Story, M.-A., Smith, B., & and the NCBO team (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000523 · Cited by 276
Self-citationThe role of data mining in pharmacovigilance
Hauben, M., Madigan, D., Gerrits, C. M., Walsh, L., & Van Puijenbroek, E. P. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.5.929 · Cited by 276
Self-citationNovel Statistical Tools for Monitoring the Safety of Marketed Drugs
Almenoff, J. S., Pattishall, E. N., Gibbs, T. G., DuMouchel, W., Evans, S. J. W., & Yuen, N. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100258 · Cited by 266
Self-citationColoma, P. M., Schuemie, M. J., Trifirò, G., Gini, R., Herings, R., Hippisley‐Cox, J., Mazzaglia, G., Giaquinto, C., Corrao, G., Pedersen, L., et al. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2053 · Cited by 259
Leaman, R., Wojtulewicz, L. B., Sullivan, R., Skariah, A. M., Yang, J. G., & Gonzalez‐Hernandez, G. (2010) · Cited by 256
A basic study design for expedited safety signal evaluation based on electronic healthcare data
Schneeweiss, S. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1926 · Cited by 255
Adverse drug event monitoring at the food and drug administration: Your report can make a difference
Ahmad, S. R. (2003) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2003.20130.x · Cited by 249
The New Sentinel Network — Improving the Evidence of Medical-Product Safety
Platt, R., Wilson, M., Chan, K. A., Benner, J. S., Marchibroda, J., & McClellan, M. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0905338 · Cited by 228
Tatonetti, N. P., Denny, J. C., Murphy, S. N., Fernald, G. H., Krishnan, G., Castro, V, Yue, P., Tsau, P. S., Kohane, I., Roden, D. M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.83 · Cited by 201
Mining multi-item drug adverse effect associations in spontaneous reporting systems
Harpaz, R., Chase, H. S., & Friedman, C. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-s9-s7 · Cited by 171
Self-citationDecision support methods for the detection of adverse events in post-marketing data
Hauben, M., & Bate, A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.12.012 · Cited by 163
Accounting for Multiplicities in Assessing Drug Safety: A Three‐Level Hierarchical Mixture Model
Berry, S. M., & Berry, D. A. (2004) · Biometrics · doi:10.1111/j.0006-341x.2004.00186.x · Cited by 158
Patrick, A. R., Schneeweiß, S., Brookhart, M. A., Glynn, R. J., Rothman, K. J., Avorn, J., & Stürmer, T. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2098 · Cited by 144
Data mining for signals in spontaneous reporting databases: proceed with caution
Stephenson, W. P., & Hauben, M. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1323 · Cited by 135
Predicting Adverse Drug Events Using Pharmacological Network Models
Cami, A., Arnold, A. D., Manzi, S. F., & Reis, B. Y. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002774 · Cited by 135
Disproportionality methods for pharmacovigilance in longitudinal observational databases
Zorych, I., Madigan, D., Ryan, P. B., & Bate, A. (2011) · Statistical Methods in Medical Research · doi:10.1177/0962280211403602 · Cited by 128
Self-citationBrown, J. S., Kulldorff, M., Chan, K. A., Davis, R. L., Graham, D. J., Pettus, P. T., Andrade, S. E., Raebel, M. A., Herrinton, L. J., Roblin, D. W., et al. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1509 · Cited by 126
Almenoff, J. S., DuMouchel, W., Kindman, L. A., Yang, X., & Fram, D. M. (2003) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.885 · Cited by 124
Self-citationDrug repurposing and adverse event prediction using high‐throughput literature analysis
Deftereos, S., Andronis, C., Friedla, E. J., Persidis, A., & Persidis, A. (2011) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.147 · Cited by 121
Annotation Analysis for Testing Drug Safety Signals using Unstructured Clinical Notes
LePendu, P., Iyer, S. V., Fairon, C., & Shah, N. H. (2012) · Journal of Biomedical Semantics · doi:10.1186/2041-1480-3-s1-s5 · Cited by 98
Self-citationPharmacogenomics of Adverse Drug Reactions: Practical Applications and Perspectives
Becquemont, L. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.37 · Cited by 96
Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD
Schuemie, M. J. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2051 · Cited by 94
Using information mining of the medical literature to improve drug safety
Shetty, K. D., & Dalal, S. R. (2011) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000096 · Cited by 85
Ramírez, E., Carcas, A. J., Borobia, A. M., Lei, S. H., Piñana, E., Fudio, S., & Frías, J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.185 · Cited by 83
Drug Safety Reform at the FDA — Pendulum Swing or Systematic Improvement?
McClellan, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078057 · Cited by 81
Predicting Adverse Drug Reactions Using Publicly Available PubChem BioAssay Data
Pouliot, Y., Chiang, A. P.-F., & Butte, A. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.81 · Cited by 80
Biclustering of Adverse Drug Events in the FDA's Spontaneous Reporting System
Harpaz, R., Perez, H. R., Chase, H. S., Rabadán, R., Hripcsak, G. M., & Friedman, C. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.285 · Cited by 78
Self-citationMatthews, E. J., Ursem, C. J., Kruhlak, N. L., Benz, R. D., Sabaté, D., Yang, C., Klopman, G., & Contrera, J. F. (2009) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2009.01.009 · Cited by 75
Frid, A. A., & Matthews, E. J. (2009) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2009.11.005 · Cited by 73
Post-Approval Drug Safety Surveillance
Gibbons, R. D., Amatya, A. K., Brown, C. H., Hur, K., Marcus, S. M., Bhaumik, D. K., & Mann, J. J. (2010) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.012809.103649 · Cited by 73
Brownstein, J. S., Sordo, M., Kohane, I. S., & Mandl, K. D. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000840 · Cited by 69
Caster, O., Norén, G. N., Madigan, D., & Bate, A. (2010) · Statistical Analysis and Data Mining The ASA Data Science Journal · doi:10.1002/sam.10078 · Cited by 67
Self-citationVilar, S., Harpaz, R., Chase, H. S., Costanzi, S., Rabadán, R., & Friedman, C. (2011) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000417 · Cited by 64
Self-citationDesign considerations in an active medical product safety monitoring system.
Gagne, J. J., Fireman, B., Ryan, P. B., Maclure, M., Gerhard, T., Toh, S., Rassen, J. A., Nelson, J. C., & Schneeweiss, S. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2316 · Cited by 49
Self-citationData-Driven Methods to Discover Molecular Determinants of Serious Adverse Drug Events
Chiang, A. P.-F., & Butte, A. J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.274 · Cited by 48
An Evaluation of Three Signal-Detection Algorithms Using a Highly Inclusive Reference Event Database
Hochberg, A. M., Hauben, M., Pearson, R. K., O’Hara, D. J., Reisinger, S. J., Goldsmith, D. I., Gould, A. L., & Madigan, D. (2009) · Drug Safety · doi:10.2165/00002018-200932060-00007 · Cited by 47
Self-citationDeshpande, G., Gogolak, V., & Smith, S. W. (2010) · Pharmaceutical Medicine · doi:10.1007/bf03256796 · Cited by 45
Managing Drug-Risk Information — What to Do with All Those New Numbers
Avorn, J., & Schneeweiß, S. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0905466 · Cited by 42
The use and misuse of matching in case-control studies: the example of polycystic ovary syndrome
Bloom, M. S., Schisterman, E. F., & Hediger, M. L. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.11.125 · Cited by 40
Ball, R., & Botsis, T. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.119 · Cited by 39
Commentary: What Can We Really Learn From Observational Studies?
Madigan, D., & Ryan, P. B. (2011) · Epidemiology · doi:10.1097/ede.0b013e318228ca1d · Cited by 27
Self-citationStang, P., Ryan, P. B., Dusetzina, S. B., Hartzema, A. G., Reich, C., Overhage, J. M., & Racoosin, J. A. (2011) · Health Outcomes Research in Medicine · doi:10.1016/j.ehrm.2011.11.003 · Cited by 18
Self-citationHigh-Performance Signal Detection for Adverse Drug Events using MapReduce Paradigm.
Fan, K., Sun, X., Tao, Y., Xu, L., Wang, C., Mao, X.-L., Peng, B., & Pan, Y. (2010) · PubMed · Cited by 9
Self-controlled methods for postmarketing drug safety surveillance in large-scale longitudinal data
Simpson, S. (2011) · doi:10.7916/d8zk5ppq · Cited by 8
Cited by
Drug repurposing: a promising tool to accelerate the drug discovery process
Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.014 · Cited by 597
Nikfarjam, A., Sarker, A., O’Connor, K., Ginn, R., & Gonzalez, G. (2015) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocu041 · Cited by 543
Utilizing social media data for pharmacovigilance: A review
Sarker, A., Ginn, R., Nikfarjam, A., O’Connor, K., Smith, K., Jayaraman, S., Upadhaya, T., & Gonzalez, G. (2015) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2015.02.004 · Cited by 497
Computational Drug Repositioning: From Data to Therapeutics
Hurle, M. R., Yang, L., Xie, Q., Rajpal, D. K., Sanseau, P., & Agarwal, P. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.1 · Cited by 373
Portable automatic text classification for adverse drug reaction detection via multi-corpus training
Sarker, A., & Gonzalez, G. (2015) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2014.11.002 · Cited by 356
Metadata
- Authors
- Harpaz, R., DuMouchel, W., Shah, N. H., Madigan, D., Ryan, P., & Friedman, C.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2012-05-02
- Volume
- 91
- Issue
- 6
- Pages
- 1010-1021
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2123089829
- Cited by
- 393
- References
- 64
- FWCI
- 40.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.